Pentamethylquercetin (PMQ) reduces thrombus formation by inhibiting platelet function

Sci Rep. 2015 Jun 10:5:11142. doi: 10.1038/srep11142.

Abstract

Flavonoids exert both anti-oxidant and anti-platelet activities in vitro and in vivo. Pentamethylquercetin (PMQ), a polymethoxylated flavone derivative, has been screened for anti-carcinogenic and cardioprotective effects. However, it is unclear whether PMQ has anti-thrombotic effects. In the present study, PMQ (20 mg/kg) significantly inhibited thrombus formation in the collagen- epinephrine- induced acute pulmonary thrombosis mouse model and the ferric chloride-induced carotid injury model. To explore the mechanism, we evaluated the effects of PMQ on platelet function. We found that PMQ inhibited platelet aggregation and granule secretion induced by low dose agonists, including ADP, collagen, thrombin and U46619. Biochemical analysis revealed that PMQ inhibited collagen-, thrombin- and U46619-induced activation of Syk, PLCγ2, Akt, GSK3β and Erk1/2. Therefore, we provide the first report to show that PMQ possesses anti-thrombotic activity in vivo and inhibited platelet function in vitro, suggesting that PMQ may represent a potential therapeutic candidate for the prevention or treatment of thrombotic disorders.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • 15-Hydroxy-11 alpha,9 alpha-(epoxymethano)prosta-5,13-dienoic Acid / pharmacology
  • Animals
  • Blood Platelets / cytology
  • Blood Platelets / drug effects*
  • Mice
  • Mice, Inbred C57BL
  • Platelet Aggregation Inhibitors / pharmacology*
  • Quercetin / analogs & derivatives*
  • Quercetin / pharmacology
  • Thrombin / pharmacology
  • Thrombosis / prevention & control*

Substances

  • 3,3',4',5,7-pentamethylquercetin
  • Platelet Aggregation Inhibitors
  • 15-Hydroxy-11 alpha,9 alpha-(epoxymethano)prosta-5,13-dienoic Acid
  • Quercetin
  • Thrombin